Pan-PI3K Inhibitor Voxtalisib Active in FL but Less So in CLL, DLBCL
In a phase II study, voxtalisib, which targets all four class I PI3Ks, had efficacy in FL but limited clinical effect in MCL, DLBCL, and CLL/SLL. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news
International CLL Group Updates Trials Guidelines
The International Workshop on Chronic Lymphocytic Leukemia has updated its 2008 consensus guidelines for design and conduct of CLL clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia News Source Type: news
Starting With Ibrutinib May Help Some Leukemia Patients Achieve Complete Response Starting With Ibrutinib May Help Some Leukemia Patients Achieve Complete Response
In patients with chronic lymphocytic leukemia (CLL), initial therapy with ibrutinib is among the factors that increase the likelihood of a complete response, according to pooled data from two trials.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CLL Responds to Induction With RCC Regimen Plus Rituximab Maintenance
CLL patients responded well to induction with the RCC regimen cladribine, cyclophosphamide, and rituximab followed by maintenance rituximab. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology Source Type: news
Single-Agent Ibrutinib Active at 5 Years in CLL, SLL
Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology News Source Type: news
